title: Ovarian ALK+ diffuse large B-cell lymphoma: a case report and a review of the literature.
abstract: Through this case presentation and a review of the literature, we aim to describe clinical and pathologic features and to distinguish the outcome of these tumors. A 25-year-old woman presented with pelvic pain and an iliac mass. Workup revealed a 53-mm cystic partitioned mass of the left ovary infiltrating the left sacrum. She underwent a left adnexectomy. Gross examination revealed a ruptured ovarian mass. When dissected, it showed grayish cerebroid aspects. Histologic examination revealed a malignant tumor proliferation of the diffuse large cells. An immunohistochemical analysis showed negative results for PLAP, αFP, βHCG, CD117, CK20, and CD30. It also showed lack of B markers and T marker (CD3) and an expression of CD138 and anaplastic lymphoma kinase. The patient was treated by 6 cycles of CHOP chemotherapy and a pelvic radiotherapy. She presented with a 15-cm splenomegaly 26 months later and died of febrile neutropenia. Most patients follow an aggressive disease and are unlikely to respond to the standard.
authors.affiliation: Department of Pathology Salah Azaiez Institute, Tunis, Tunisia.
authors.forename: Rym
authors.initials: R
authors.lastname: Sellami-Dhouib
authors.forename: Asma
authors.initials: A
authors.lastname: Nasfi
authors.forename: Nesrine Turki
authors.initials: NT
authors.lastname: Mejri
authors.forename: Raoudha
authors.initials: R
authors.lastname: Doghri
authors.forename: Lamia
authors.initials: L
authors.lastname: Charfi
authors.forename: Samia
authors.initials: S
authors.lastname: Sassi
authors.forename: Imen
authors.initials: I
authors.lastname: Abbes
authors.forename: Karima
authors.initials: K
authors.lastname: Mrad
authors.forename: Naziha
authors.initials: N
authors.lastname: Ben Hamida
authors.forename: Maha P
authors.initials: MP
authors.lastname: Driss
authors.forename: Khaled
authors.initials: K
authors.lastname: Ben Romdhane
mesh_terms: D000328:Adult; D000077548:Anaplastic Lymphoma Kinase; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002454:Cell Differentiation; D003520:Cyclophosphamide / Q000008:administration & dosage; D003937:Diagnosis, Differential; D004317:Doxorubicin / Q000008:administration & dosage; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D016393:Lymphoma, B-Cell / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D011241:Prednisone / Q000008:administration & dosage; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases; D011241:Prednisone